Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors

Annals of Nuclear Medicine

Volumn 22, Issue 4, 2008, Pages 237-243

  Namwongprom, Sirianong ^a,b   Wong, Franklin C ^a   Tateishi, Ukihide ^a   Kim, Edmund E ^a   Boonyaprapa, Sombut ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Carcinoid tumors; Chromogranin A; Somatostatin receptor scintigraphy

Indexed keywords

CHROMOGRANIN A; PENTETREOTIDE TC 99M; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER TISSUE; CARCINOID; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDGUT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; THORAX RADIOGRAPHY; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOID TUMOR; CHROMOGRANIN A; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PENTETIC ACID; PROGNOSIS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; WHOLE BODY IMAGING;

EID: 44949093441     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0123-y     Document Type: Article

References (41)

1. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338-352.
2. Newton JN, Swerdlow AJ, dos Santos Silva IM, Vessey MP, Grahame-Smith DG, Primatesta P, et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994;70:939-942.
3. Modlin M, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829.
4. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;1:238-239.
5. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858-865.
6. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognosis factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-690.
7. Angeletti RH. Chromogranins and neuroendocrine secretion. Lab Invest 1986;55:387-390.
8. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991;12:181-187.
9. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992;49:497-528.
10. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours (review). Eur J Clin Invest 1998;28:431-440.
11. Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours (review). Anticancer Res 1999;19:3415-3427.
12. Drivsholm L, Paloheimo LI, Osterlind K. Chromogranin A: a significant prognostic factor in small cell lung cancer. Br J Cancer 1999;81:667-671.
13. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentration in small cell lung carcinoma. Ann Intern Med 1986;105:698-700.
14. Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 1993;32:197-201.
15. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547-553.
16. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
17. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-858.
18. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-347.
19. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
20. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-3459.
21. Benalia N, Gerjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000;62Suppl 1:27-32.
22. Kvols L, Brown M, O'Connor M, Hung JC, Hayostek RJ, Reubi JC, et al. Evaluation of radiolabeled somatostatin analogue (I-123 octreotide) in the detection and localization of carcinoid and islet tumors. Radiology 1993;187:129-133.
23. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SEJ. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993;20:283-292.
24. Lamberts SWJ, Reubi JC, Krenning EP. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrne tumours. Acta Oncol 1993;32:167-170.
25. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as a serum marker for neuroendocrine neoplasia: comparison with neuron-specific-enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-2628.
26. Oberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-690.
27. Seregni D, Ferrari L, Bajetta E, Aartinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12Suppl 2:S69-S72.
28. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144:49-59.
29. Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surg Oncol 2000;9:173-179.
30. Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000;44:22-41.
31. Baudin D, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffie P, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 2001;12Suppl 2:S79-S82.
32. O'Connor DT, Pandian MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631-1637.
33. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955-964.
34. Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997;136:67-73.
35. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JH, Parmer RJ, O'Connor DT. Chromogranin A: storage and release in hypertension. Hypertension 1990;15:237-246.
36. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997;32:198-202.
37. Sanduleanu S, Stridsberg M, Jonkers D, Hameetemna W, Deimond I, Lundqvist G, et al. Serum gastrin and chromogranin A during meals. Aliment Pharmacol Ther 1999;13:145-153.
38. Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999;84:2712-2717.
39. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
40. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings. Prostate 1997;30:1-6.
41. Eriksson B, Arnberg H, Lindgren PG, Lorelius LE, Magnusson A, Lundqvist G, et al. Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990;228:103-113.